Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Comparison of (211)At-PRIT and (211)At-RIT of Ovarian Microtumors in a Nude Mouse Model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Towards elucidating the radiochemistry of astatine - Behavior in chloroform

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Multifunctional Clickable Reagents for Rapid Bioorthogonal Astatination and Radio-Crosslinking

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Sture Lindegren
  • Per Albertsson
  • Tom Bäck
  • Holger Jensen
  • Stig Palm
  • Emma Aneheim
Vis graf over relationer

Despite the consensus around the clinical potential of the α-emitting radionuclide astatine-211 (211At), there are only a limited number of research facilities that work with this nuclide. There are three main reasons for this: (1) Scarce availability of the nuclide. Despite a relatively large number of globally existing cyclotrons capable of producing 211At, few cyclotron facilities produce the nuclide on a regular basis. (2) Lack of a chemical infrastructure, that is, isolation of 211At from irradiated targets and the subsequent synthesis of an astatinated product. At present, the research groups that work with 211At depend on custom systems for recovering 211At from the irradiated targets. Setting up and implementing such custom units require long lead times to provide a proper working system. (3) The chemistry of 211At. Compared with radiometals there are no well-established and generally accepted synthesis methods for forming sufficiently stable bonds between 211At and the tumor-specific vector to allow for systemic applications. Herein we present an overview of the infrastructure of producing 211At radiopharmaceuticals, from target to radiolabeled product including chemical strategies to overcome hurdles for advancement into clinical trials with 211At.

OriginalsprogEngelsk
TidsskriftCancer Biotherapy & Radiopharmaceuticals
Vol/bind35
Udgave nummer6
Sider (fra-til)425-436
Antal sider12
ISSN1084-9785
DOI
StatusUdgivet - aug. 2020

ID: 62414449